Hypoxia-induced secretory autophagy in cancer-associated fibroblasts promotes ECM remodelling through serglycin secretion in oral squamous cell carcinoma

Abstract

Background: The worst pattern of invasion (WPOI) is a critical histological prognostic indicator in oral squamous cell carcinoma (OSCC), yet the underlying mechanisms driving high WPOI remain poorly understood. While cancer-associated fibroblasts (CAFs) and their secreted factor serglycin (SRGN) are implicated in tumour progression, the regulation of SRGN secretion within the hypoxic tumour microenvironment is unknown.

Methods: We performed single-cell RNA sequencing (scRNA-seq) on 6 OSCC samples (3 each of WPOI 1–3 and 4–5) to identify subgroups of CAFs and their characteristic gene expression profiles. Using Western blot, qRT-PCR, and immunofluorescence, we investigated hypoxia-induced SRGN secretion pathways. Complementary CRISPR-Cas9 knockout, Co-IP assays, and xenograft models elucidated SRGN's role in ECM remodelling.

Results: ScRNA-seq revealed significant enrichment of CAFs, particularly an SRGN-expressing myCAF subpopulation, in high-WPOI (4–5) OSCC tissues. Under hypoxia, CAFs switched SRGN secretion from the conventional ER-Golgi pathway to an unconventional secretory autophagy pathway, dependent on autophagosome formation but independent of lysosomal degradation. Secreted SRGN directly interacted with matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9) in the extracellular matrix (ECM), enhancing ECM remodelling and OSCC invasion and migration. In vivo, either genetic ablation of SRGN in CAFs or pharmacological inhibition of autophagy significantly suppressed tumour growth, inhibited collagen I degradation, and restored E-cadherin expression.

Conclusion: Our study identifies a novel mechanism whereby hypoxia induces CAFs to secrete SRGN via secretory autophagy. This SRGN-MMP2/9 axis drives ECM remodelling and promotes OSCC invasion, which histologically manifests as high WPOI. Targeting secretory autophagy or SRGN represents a promising therapeutic strategy for aggressive OSCC.

Keywords

cancer-associated fibroblasts / ECM remodelling / secretory autophagy / serglycin

References

[1] Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021; 127(16): 3029-3030.

[2] Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005; 29(2): 167-178.

[3] Ding L, Fu Y, Zhu N, et al. OXTRHigh stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling. Nat Commun. 2022; 13(1): 5124.

[4] Bryne M, Koppang HS, Lilleng R, et al. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med. 1989; 18(8): 432-437.

[5] Chatterjee D, Bansal V, Malik V, et al. Tumor budding and worse pattern of invasion can predict nodal metastasis in oral cancers and associated with poor survival in early-stage tumors. Ear Nose Throat J. 2019; 98(7): E112-E119.

[6] Almangush A, Bello IO, Coletta RD, et al. For early-stage oral tongue cancer, depth of invasion and worst pattern of invasion are the strongest pathological predictors for locoregional recurrence and mortality. Virchows Arch. 2015; 467: 39-46.

[7] Loh JJ, Ma S. The role of cancer-associated fibroblast as a dynamic player in mediating cancer stemness in the tumor microenvironment. Front Cell Dev Biol. 2021; 9:727640.

[8] Chen Y, Zhang X, Yang H, et al. The “Self-eating” of cancer-associated fibroblast: a potential target for cancer. Biomed Pharmacother. 2023; 163:114762.

[9] Feng X, Zhang H, Meng L, et al. Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5. Autophagy. 2021; 17(3): 723-742.

[10] Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006; 10(1): 51-64.

[11] Feng Y, Chen Y, Wu X, et al. Interplay of energy metabolism and autophagy. Autophagy. 2024; 20(1): 4-14.

[12] Ponpuak M, Mandell MA, Kimura T, et al. Secretory autophagy. Curr Opin Cell Biol. 2015; 35: 106-116.

[13] Korpetinou A, Skandalis SS, Labropoulou VT, et al. Serglycin: at the crossroad of inflammation and malignancy. Front Oncol. 2014; 3: 327.

[14] Wang X, Xiong H, Liang D, et al. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients. BMC Cancer. 2020; 20(1): 378.

[15] Zhang Z, Qiu N, Yin J, et al. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics. 2020; 10(10): 4290.

[16] Zhang Z, Deng Y, Zheng G, et al. SRGN-TGFβ2 regulatory loop confers invasion and metastasis in triple-negative breast cancer. Oncogenesis. 2017; 6(7): e360-e360.

[17] Tanaka I, Dayde D, Tai MC, et al. SRGN-triggered aggressive and immunosuppressive phenotype in a subset of TTF-1–negative lung adenocarcinomas. J Natl Cancer Inst. 2022; 114(2): 290-301.

[18] Yan D, Cui D, Zhu Y, et al. M6PR-and EphB4-rich exosomes secreted by serglycin-overexpressing esophageal cancer cells promote cancer progression. Int J Biol Sci. 2023; 19(2): 625.

[19] Wang YL, Ren D, Lu JL, et al. STAT3 regulates SRGN and promotes metastasis of nasopharyngeal carcinoma through the FoxO1-miR-148a-5p-CREB1 axis. Lab Invest. 2022; 102(9): 919-934.

[20] Xu Y, Xu J, Yang Y, et al. SRGN promotes colorectal cancer metastasis as a critical downstream target of HIF-1α. Physiol Biochem. 2018; 48(6): 2429-2440.

[21] Xie J, Qi X, Wang Y, et al. Cancer-associated fibroblasts secrete hypoxia-induced serglycin to promote head and neck squamous cell carcinoma tumor cell growth in vitro and in vivo by activating the Wnt/β-catenin pathway. Cell Oncol. 2021; 44(3): 661-671.

[22] Jin R, Zhou W, Xu Y, et al. Electrochemical visualization of membrane proteins in single cells at a nanoscale using scanning electrochemical cell microscopy. Anal Chem. 2023; 95(27): 10172-10177.

[23] Rheinlaender J, Schäffer TE. Mapping the mechanical stiffness of live cells with the scanning ion conductance microscope. Soft Matter. 2013; 9(12): 3230-3236.

[24] Jin W, Yu Q, Yu L, et al. HAS1high cancer associated fibroblasts located at the tumor invasion front zone promote oral squamous cell carcinoma invasion via ECM remodeling. J Exp Clin Cancer Res. 2025; 44(1): 238.

[25] Wang Y, Wang R, Li B, et al. Cancer-associated fibroblasts in the invasive tumour front promote the metastasis of oral squamous cell carcinoma through MFAP5 upregulation. Gene. 2023; 876:147504.

[26] Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, et al. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020; 11: 5120.

[27] Gao L, Dou ZC, Ren WH, et al. CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival via AKT/ERK½/mTOR signaling pathways in oral squamous cell carcinomas. Cell Death Dis. 2019; 10(10): 745.

[28] Wu YT, Tan HL, Shui G, et al. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem. 2010; 285(14): 10850-10861.

[29] Ronan B, Flamand O, Vescovi L, et al. A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol. 2014; 10(12): 1013-1019.

[30] Deretic V, Jiang S, Dupont N. Autophagy intersections with conventional and unconventional secretion in tissue development, remodeling and inflammation. Trends Cell Biol. 2012; 22(8): 397-406.

[31] Liaci AM, Förster F. Take me home, protein roads: structural insights into signal peptide interactions during ER translocation. Int J Mol Sci. 2021; 22(21):11871.

[32] Nebenführ A, Ritzenthaler C, Robinson DG. Brefeldin A: deciphering an enigmatic inhibitor of secretion. Plant Physiol. 2002; 130(3): 1102-1108.

[33] Kimura T, Jia J, Kumar S, et al. Dedicated SNARE s and specialized TRIM cargo receptors mediate secretory autophagy. EMBO J. 2017; 36(1): 42-60.

[34] Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018; 14(8): 1435-1455.

[35] Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998; 23(1): 33-42.

[36] Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018; 81: 241-330.

[37] Cui J, Dean D, Hornicek FJ. The role of extracelluar matrix in osteosarcoma progression and metastasis. J Exp Clin Cancer Res. 2020; 39: 1-11.

[38] Humphries MJ. Cell adhesion assays. Methods Mol Biol. 2009; 522: 203-210.

[39] Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018; 18(9): 533-548.

[40] Guo JY, Hsu HS, Tyan SW, et al. Serglycin in tumor microenvironment promotes non-small cell lung cancer aggressiveness in a CD44-dependent manner. Oncogene. 2017; 36(17): 2457-2471.

[41] Bouris P, Manou D, Sopaki-Valalaki A, et al. Serglycin promotes breast cancer cell aggressiveness: induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling. Matrix Biol. 2018; 74: 35-51.

[42] Hendrayani SF, Al-Harbi B, Al-Ansari MM, et al. The inflammatory/cancer-related IL-6/STAT3/NF-κB positive feedback loop includes AUF1 and maintains the active state of breast myofibroblasts. Oncotarget. 2016; 7(27):41974.

[43] Sasahara A, Tominaga K, Nishimura T, et al. An autocrine/paracrine circuit of growth differentiation factor (GDF) 15 has a role for maintenance of breast cancer stem-like cells. Oncotarget. 2017; 8(15):24869.

[44] Jimenez-Pascual A, Hale JS, Kordowski A, et al. ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells. Cancer discovery. 2019; 9(11): 1574-1589.

[45] Selvam S, , Ganesan D, et al. Autophagy inhibition by biotin elicits endoplasmic reticulum stress to differentially regulate adipocyte lipid and protein synthesis. Cell Stress Chaperones. 2019; 24(2): 343-350.

[46] Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. Science. 2020; 368(6489):eaat5314.

[47] New J, Arnold L, Ananth M, et al. Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target. Cancer research. 2017; 77(23): 6679-6691.

[48] Dupont N, Jiang S, Pilli M, et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1β. EMBO J. 2011; 30(23): 4701-4711.

[49] Noh SH, Gee HY, Kim Y, et al. Specific autophagy and ESCRT components participate in the unconventional secretion of CFTR. Autophagy. 2018; 14(10): 1761-1778.

[50] Chen YD, Fang YT, Cheng YL, et al. Exophagy of annexin A2 via RAB11, RAB8A and RAB27A in IFN-γ-stimulated lung epithelial cells. Sci Rep. 2017; 7(1): 5676.

[51] Bruns C, McCaffery JM, Curwin AJ, et al. Biogenesis of a novel compartment for autophagosome-mediated unconventional protein secretion. J Cell Biol. 2011; 195(6): 979-992.

[52] Duran JM, Anjard C, Stefan C, et al. Unconventional secretion of Acb1 is mediated by autophagosomes. J Cell Biol. 2010; 188(4): 527-536.

[53] Li Q, Peng G, Liu H, et al. Molecular mechanisms of secretory autophagy and its potential role in diseases. Life Sci. 2024; 347:122653.

[54] Wang X, Wu R, Zhai P, et al. Hypoxia promotes EV secretion by impairing lysosomal homeostasis in HNSCC through negative regulation of ATP6V1A by HIF-1α. J Extracell Vesicles. 2023; 12(2):e12310.

[55] Abokyi S, Shan SW, To C, et al. Autophagy upregulation by the TFEB inducer trehalose protects against oxidative damage and cell death associated with NRF2 inhibition in human RPE cells. Oxid Med Cell Longevity. 2020; 2020(1):5296341.

[56] Li C, Wang X, Li X, et al. Proteasome inhibition activates autophagy-lysosome pathway associated with TFEB dephosphorylation and nuclear translocation. Front Cell Dev Biol. 2019; 7: 170.

[57] Manou D, Golfinopoulou MA, Alharbi SND, et al. The expression of serglycin is required for active transforming growth factor β receptor I tumorigenic signaling in glioblastoma cells and paracrine activation of stromal fibroblasts via CXCR-2. Biomolecules. 2024; 14(4): 461.

[58] Zhu Y, Lam AKY, Shum DKY, et al. Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer. Theranostics. 2021; 11(6): 2722-2741.

[59] Li XJ, Ong CK, Cao Y, et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer research. 2011; 71(8): 3162-3172.

[60] Zhu Y, Lam AKY, Shum DKY, et al. Significance of serglycin and its binding partners in autocrine promotion of metastasis in esophageal cancer. Theranostics. 2021; 11(6): 2722.

[61] Xu H, Ren SM, Wang Y, et al. Abnormal activation of the Ras/MAPK signaling pathway in oncogenesis and progression. Cancer Adv. 2025; 8:e25002.

[62] Gomes LR, Terra LF, Wailemann RA, et al. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer. 2012; 12: 26.

[63] Vishnubhotla R, Bharadwaj S, Sun S, et al. Treatment with Y-27632, a ROCK inhibitor, increases the proinvasive nature of SW620 cells on 3D collagen type 1 matrix. Int J Cell Biol. 2012; 2012(1):259142.

[64] Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991; 113(1): 173-185.

[65] Costa PMDS, Sales SLA, Pinheiro DP, et al. Epigenetic reprogramming in cancer: from diagnosis to treatment. Front Cell Dev Biol. 2023; 11:1116805.

[66] Theivendran S, Xian H, Qu J, et al. A pioglitazone nanoformulation designed for cancer-associated fibroblast reprogramming and cancer treatment. Nano Letters. 2024; 24(15): 4354-4361.

[67] Alcaraz J, Ikemori R, Llorente A, et al. Epigenetic reprogramming of tumor-associated fibroblasts in lung cancer: therapeutic opportunities. Cancers. 2021; 13(15): 3782.

[68] Man K, Mekhileri NV, Lim KS, et al. MI192 induced epigenetic reprogramming enhances the therapeutic efficacy of human bone marrows stromal cells for bone regeneration. Bone. 2021; 153:116138.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.